Lastly, it is important to note that a sizable fraction of the general population (2.5%) harbors single-nucleotide polymorphisms that inactivate the tumor suppressor activity of PTPN12, but the majority of these individuals do not develop cancer. Therefore, loss of PTPN12 alone is not sufficient to drive tumor formation. Interestingly, the effect of PTPN12 appears confined to the ERK/RSK pathway, without affecting the important PI3K/Akt pathway. This observation suggests that PTPN12 loss cooperates with mutations in other pathways, including the PI3K/Akt pathway, which is hyperactivated in nearly 50% of breast cancers. These considerations together lead us to conclude that, although PTPN12 may be an important piece of the triple-negative breast cancer puzzle, it is still a member of an even larger constellation of alterations that together drive this recalcitrant malignancy.
The target of rapamycin complex 2 (TORC2) is a key regulator of cell growth. Zinzalla et al. (2011) now provide evidence that TORC2 is activated by direct association with the ribosome, which may ensure that TORC2 activity is calibrated to match the cell's intrinsic growth capacity.
TOR is an atypical serine/threonine protein kinase conserved from yeast to mammals that forms two distinct physical and functional complexes termed TORC1 and TORC2 (Figure 1 ) (Wullschleger et al., 2006) . TORC1, a rapamycin-sensitive complex, regulates translation, autophagy, cell growth, and cell size. In contrast, TORC2 is not directly inhibited by rapamycin and controls cell survival and morphology. The frequent dysregulation of mammalian TOR (mTOR) signaling observed in human cancer is thought to contribute to tumorigenesis (Zoncu et al., 2011) . Extensive studies have revealed the molecular mechanisms of mTORC1 regulation in response to signals, such as growth factors, cellular energy status, nutrient availability, and stress. Although compelling evidence has placed TORC2 downstream of phosphatidylinositol 3-kinase (PI3K) and upstream of the serine/threonine kinase AKT, it has been unknown how TORC2 is regulated (Wullschleger et al., 2006) . Using a combination of elegant genetic screening and sophisticated biochemical studies, Zinzalla et al. (2011) significantly advance our understanding of TOR biology by identifying the ribosome as a missing link between PI3K and mTORC2 ( Figure 1 ).
In yeast, TORC2 phosphorylates and activates YPK2, the ortholog of mammalian kinase SGK1, a known substrate of mammalian TORC2. Loss of TORC2 function is lethal in yeast; however, overexpression of a constitutively active YPK2 suppresses the lethality caused by a loss-of-function TORC2 mutation (Kamada et al., 2005) . Zinzalla et al. designed a clever reverse suppressor screen in search of yeast mutants that require the expression of constitutively active YPK2 for survival. This strategy was aimed at uncovering mutations in TORC2 upstream activators. Perhaps not surprisingly, many mutations isolated were found in genes encoding components of TORC2. Interestingly, the only non-TORC2 component isolated was NIP7, which encodes a protein involved in the maturation of rRNA and ribosome biogenesis. Survival of NIP7 mutant yeast requires overexpression of the constitutively active YPK2. Many scientists would abstain from studying ribosomal proteins because their inactivation may disrupt protein translation and lead to pleiotropic effects. Undeterred, Hall and colleagues investigated further, eventually discovering an exciting biochemical mechanism linking the ribosome to TORC2 activation.
The genetic studies not only confirm a role for NIP7 in TORC2 activation, but also show that ribosomal proteins are important for TORC2 function in yeast. Mutation of NIP7 mimics the TORC2 loss-of-function phenotypes, indicating a strong functional relationship between these two genes. The authors further extended their study to mammalian cells and show that mammalian NIP7 (mNIP7) and ribosome assembly are important for mTORC2 activation. Knockdown of mNIP7 reduces mTORC2 activity, as indicated by a decrease in the phosphorylation of mTORC2 substrates. Moreover, knockdown of either Rpl7 (a subunit of the 60S ribosome) or Rps16 (a subunit of the 40S ribosome) inactivates mTORC2, demonstrating the importance of ribosome in mTORC2 activation. Inhibition of protein translation had no effect on mTORC2 activation, supporting the notion that mTORC2 is activated by the ribosome, but not translation. Additionally, extensive biochemical studies demonstrate that mTORC2 can associate with the ribosome, and the ribosomalassociated mTORC2 displays kinase activity toward AKT in vitro. It appears that the mTORC2 components, rictor and/or sin1, which are not found in TORC1, interact with the 60S subunit of ribosome.
Importantly, the authors link this association with known upstream regulators of TORC2, demonstrating that the interaction between ribosome and TORC2 is strongly enhanced by insulin stimulation. Inhibition of PI3K activity blocks the interaction between the ribosome and mTORC2, as well as inhibits mTORC2 activation in response to insulin. Complementary activation of PI3K by knockdown of PTENa tumor suppressor lipid phosphatase that counters PI3K signaling-increases the interaction between mTORC2 and ribosome, demonstrating the necessary and sufficient role of PI3K in regulating the mTORC2-ribosomal association and thus mTORC2 activation. The role of PI3K in promoting the interaction of mTORC2 and ribosome was further validated in multiple cancer cell lines with high PI3K signaling. Collectively, the study by Zinzalla et al. has convincingly demonstrated that the PI3K-dependent mTORC2-ribosome interaction plays a major role in TORC2 activation. Interestingly, Oh et al. (2010) have also recently reported the association of mTORC2 with the ribosome and propose that the ribosomal association is important for the cotranslational phosphorylation of the AKT turn motif.
The findings of Zinzalla et al. raise many interesting questions. How is the interaction between mTORC2 and the ribosome regulated? There may be intermediate players between PI3K and the TORC2-ribosome interaction. For example, phosphorylation of rictor may play a role (Dibble et al., 2009; Treins et al., 2010) . Is the interaction between TORC2 and the ribosome regulated in yeast? And if so, by what signals? The TORC2-ribosome interaction is conserved from yeast to mammals; however, there is no evidence that yeast TORC2 is activated in a PI3K-dependent manner as in mammalian cells.
How could mTORC2 be responsible for phosphorylating two different sites on the same protein with drastically different manners of regulation? mTORC2 phosphorylates both the hydrophobic motif and the turn motif of AKT. Notably, phosphorylation of the hydrophobic motif is posttranslational and induced in a PI3K-dependent manner, whereas phosphorylation of the turn motif is cotranslational and constitutive (Oh et al., 2010) . Ribosomal association may explain the constitutive and cotranslational phosphorylation of the turn motif in AKT (Figure 1) . Membrane association has been suggested to be important for AKT hydrophobic motif phosphorylation. Does this imply that there are two different pools of mTORC2?
What is the exact role of the ribosome in mTORC2 activation? Does ribosome binding regulate mTORC2 function by affecting localization, contributing to activation, or maintaining an active mTORC2 kinase?
Lastly, why the ribosome? As pointed out by Zinzalla et al., ribosome content reflects the cell's potential for growth. Therefore, a mechanism that involves the ribosome may ensure that TORC2 activation is tightly linked with the cell's ability to respond to growth signals. In addition, given that TORC1 regulates ribosome biogenesis, this study suggests a possible interplay between the two TORC complexes, in which TORC2 modulates TORC1 by activating AKT and TORC1 affects TORC2 by increasing ribosomal biogenesis and S6K-mediated feedback inhibition. Future studies are needed to address these important questions and possible new roles of the In response to upstream stimulation, increased phosphatidylinositol 3-kinase (PI3K) signaling activates mTORC2 (consisting of mTOR, Rictor, Sin1, and mLST8) by promoting its association with ribosomes. mTORC2 phosphorylates the C-terminal turn motif (T450) and hydrophobic motif (S473) in AKT. AKT activation also requires phosphorylation of the activation loop (T308) by PDK1. Notably, phosphorylation of the turn motif of AKT is constitutive and cotranslational, whereas phosphorylation of the hydrophobic motif is highly dependent on PI3K signaling and posttranslational. TORC2 similarly phosphorylates the turn motif and hydrophobic motif in SGK and conventional protein kinase C (García-Martínez and Alessi, 2008; Jacinto et al., 2004; Sarbassov et al., 2005) . ribosome in cellular signaling, especially in the regulation of cell growth.
Sex steroids, including testosterone, regulate the development and function of the male skeleton. Oury et al. (2011) identify a surprising new connection between the skeleton and the testis, which has implications for male fertility. They show that testosterone production in the testis is directly influenced by the bone-derived hormone osteocalcin.
The sex steroids testosterone and estrogen are essential regulators of fertility. Acting through nuclear hormone receptors expressed in somatic cells, testosterone regulates the development and maintenance of the male reproductive system and, by modulating the activity of support cells, promotes germ cell survival. Testosterone synthesis occurs within Leydig cells in the testes and is regulated by luteinizing hormone (LH) produced by the pituitary gland. In addition to LH and follicle-stimulating hormone (which is also secreted from the pituitary), there is emerging evidence that metabolic hormones such as leptin (Tena-Sempere and Barreiro, 2002) and insulin (Ma and Wittert, 2010) have impacts on testis function. Now, Oury et al. (2011) demonstrate that the skeleton may play a previously unforeseen role in control of male fertility, showing that osteocalcin (Ocn), a peptide hormone that is secreted by bone-forming osteoblast cells, directly controls testosterone production by Leydig cells in the testis (Figure 1) . Using ex vivo cell assays, the authors demonstrate that a factor that is secreted by osteoblasts, but not other skeletal cell-types, markedly increases testosterone production both by testis explants and by isolated Leydig cells. Speculating that this effect is likely to be mediated by osteocalcin, the authors show that this response is lost when Ocndeficient osteoblasts are used but is rescued in a dose-dependent manner by introduction of exogenous osteocalcin. Injection of osteocalcin also increases serum testosterone in mice. Together, these data strongly suggest that osteocalcin is indeed one of the osteoblast-secreted factors that are responsible for enhanced testosterone production.
To support their in vitro data, the authors exploit two mouse models in which osteocalcin function is either ablated (Ocn knockout mice) or enhanced (Esp knockout mice, which lack an osteotesticular phosphatase that negatively regulates osteocalcin maturation). Compared to controls, testis weight, sperm counts, and levels of circulating testosterone are all significantly reduced in Ocn knockout mice and conversely increased in Esp knockout males. Consistent with these physiological changes, Ocn-deficient males sire fewer offspring than controls, although no significant increase is observed using Esp-deficient males, possibly because the availability of oocytes acts as a limiting factor. Tissuespecific ablation of these genes in bone or testis confirms that osteocalcin derived from the skeleton acts as an endocrine factor to regulate male fertility.
How does osteocalcin influence testosterone synthesis? To identify the receptor through which osteocalcin signals, the authors postulate that, because the
